Overview of Neutralizing Antibodies and Their Potential in COVID-19

The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are useful for the determination of individual or herd imm...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2021-11, Vol.9 (12), p.1376
Main Authors: Morales-Núñez, José Javier, Muñoz-Valle, José Francisco, Torres-Hernández, Paola Carolina, Hernández-Bello, Jorge
Format: Article
Language:English
Subjects:
Antibodies
Antibody response
Antigens
Coronaviruses
COVID-19
COVID-19 vaccines
Cytotoxicity
Enzymes
Glycoproteins
Herd immunity
Infections
monoclonal antibodies
neutralization assays
Neutralizing
neutralizing antibodies
Pathogens
Peptides
Proteins
Review
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccine efficacy
Vaccines
Viral infections
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c487t-1b4999022ee2a94477c808e926bcfd5c080089e624838b77f543bb4c3e8fd01d3
cites cdi_FETCH-LOGICAL-c487t-1b4999022ee2a94477c808e926bcfd5c080089e624838b77f543bb4c3e8fd01d3
container_end_page
container_issue 12
container_start_page 1376
container_title Vaccines (Basel)
container_volume 9
creator Morales-Núñez, José Javier
Muñoz-Valle, José Francisco
Torres-Hernández, Paola Carolina
Hernández-Bello, Jorge
description The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are useful for the determination of individual or herd immunity against SARS-CoV-2, vaccine efficacy, and humoral protective response longevity, as well as supporting donor selection criteria for convalescent plasma therapy. In the current manuscript, we review the essential concepts of NAbs, examining their concept, mechanisms of action, production, and the techniques used for their detection; as well as presenting an overview of the clinical use of antibodies in COVID-19.
doi_str_mv 10.3390/vaccines9121376
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_6ab2dec5ee6a4f3d971641e938aee4c5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_6ab2dec5ee6a4f3d971641e938aee4c5</doaj_id><sourcerecordid>2615113414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-1b4999022ee2a94477c808e926bcfd5c080089e624838b77f543bb4c3e8fd01d3</originalsourceid><addsrcrecordid>eNpdkc1LHDEYh0NpqWI991YGvPQymq_Jx6Ug21YXpNuDSm8hk7yzZpmdaDKzYv96o6ui5pLw5nkf8suL0FeCDxnT-GhjnQsDZE0oYVJ8QLsUS1Ezzf59fHXeQfs5r3BZmjAl5Ge0w7gWuHTtotliA2kT4LaKXfUHpjHZPvwPw7I6HsbQRh8gV3bw1fkVhFT9jSOUuu2rMFSzxeX8Z030F_Sps32G_ad9D138_nU-O63PFifz2fFZ7biSY01arrXGlAJQqzmX0imsQFPRus43DiuMlQZBuWKqlbJrOGtb7hiozmPi2R6ab70-2pW5TmFt052JNpjHQkxLY9MYXA9G2JZ6cA2AsLxjXksiOAHNlAXgrimuH1vX9dSuwbuSqiR_I317M4Qrs4wboyQWRKsi-P4kSPFmgjyadcgO-t4OEKdsqCANIYwTXtCDd-gqTmkoX_VAUcUbhWWhjraUSzHnBN3LYwg2D_M27-ZdOr69zvDCP0-X3QOGbaaQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2612845807</pqid></control><display><type>article</type><title>Overview of Neutralizing Antibodies and Their Potential in COVID-19</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Morales-Núñez, José Javier ; Muñoz-Valle, José Francisco ; Torres-Hernández, Paola Carolina ; Hernández-Bello, Jorge</creator><creatorcontrib>Morales-Núñez, José Javier ; Muñoz-Valle, José Francisco ; Torres-Hernández, Paola Carolina ; Hernández-Bello, Jorge</creatorcontrib><description>The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are useful for the determination of individual or herd immunity against SARS-CoV-2, vaccine efficacy, and humoral protective response longevity, as well as supporting donor selection criteria for convalescent plasma therapy. In the current manuscript, we review the essential concepts of NAbs, examining their concept, mechanisms of action, production, and the techniques used for their detection; as well as presenting an overview of the clinical use of antibodies in COVID-19.</description><identifier>ISSN: 2076-393X</identifier><identifier>EISSN: 2076-393X</identifier><identifier>DOI: 10.3390/vaccines9121376</identifier><identifier>PMID: 34960121</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibodies ; Antibody response ; Antigens ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Cytotoxicity ; Enzymes ; Glycoproteins ; Herd immunity ; Infections ; monoclonal antibodies ; neutralization assays ; Neutralizing ; neutralizing antibodies ; Pathogens ; Peptides ; Proteins ; Review ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Vaccine efficacy ; Vaccines ; Viral infections ; Viruses</subject><ispartof>Vaccines (Basel), 2021-11, Vol.9 (12), p.1376</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-1b4999022ee2a94477c808e926bcfd5c080089e624838b77f543bb4c3e8fd01d3</citedby><cites>FETCH-LOGICAL-c487t-1b4999022ee2a94477c808e926bcfd5c080089e624838b77f543bb4c3e8fd01d3</cites><orcidid>0000-0002-2272-9260 ; 0000-0001-8004-1811</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2612845807/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2612845807?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34960121$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morales-Núñez, José Javier</creatorcontrib><creatorcontrib>Muñoz-Valle, José Francisco</creatorcontrib><creatorcontrib>Torres-Hernández, Paola Carolina</creatorcontrib><creatorcontrib>Hernández-Bello, Jorge</creatorcontrib><title>Overview of Neutralizing Antibodies and Their Potential in COVID-19</title><title>Vaccines (Basel)</title><addtitle>Vaccines (Basel)</addtitle><description>The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are useful for the determination of individual or herd immunity against SARS-CoV-2, vaccine efficacy, and humoral protective response longevity, as well as supporting donor selection criteria for convalescent plasma therapy. In the current manuscript, we review the essential concepts of NAbs, examining their concept, mechanisms of action, production, and the techniques used for their detection; as well as presenting an overview of the clinical use of antibodies in COVID-19.</description><subject>Antibodies</subject><subject>Antibody response</subject><subject>Antigens</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Cytotoxicity</subject><subject>Enzymes</subject><subject>Glycoproteins</subject><subject>Herd immunity</subject><subject>Infections</subject><subject>monoclonal antibodies</subject><subject>neutralization assays</subject><subject>Neutralizing</subject><subject>neutralizing antibodies</subject><subject>Pathogens</subject><subject>Peptides</subject><subject>Proteins</subject><subject>Review</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Viral infections</subject><subject>Viruses</subject><issn>2076-393X</issn><issn>2076-393X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkc1LHDEYh0NpqWI991YGvPQymq_Jx6Ug21YXpNuDSm8hk7yzZpmdaDKzYv96o6ui5pLw5nkf8suL0FeCDxnT-GhjnQsDZE0oYVJ8QLsUS1Ezzf59fHXeQfs5r3BZmjAl5Ge0w7gWuHTtotliA2kT4LaKXfUHpjHZPvwPw7I6HsbQRh8gV3bw1fkVhFT9jSOUuu2rMFSzxeX8Z030F_Sps32G_ad9D138_nU-O63PFifz2fFZ7biSY01arrXGlAJQqzmX0imsQFPRus43DiuMlQZBuWKqlbJrOGtb7hiozmPi2R6ab70-2pW5TmFt052JNpjHQkxLY9MYXA9G2JZ6cA2AsLxjXksiOAHNlAXgrimuH1vX9dSuwbuSqiR_I317M4Qrs4wboyQWRKsi-P4kSPFmgjyadcgO-t4OEKdsqCANIYwTXtCDd-gqTmkoX_VAUcUbhWWhjraUSzHnBN3LYwg2D_M27-ZdOr69zvDCP0-X3QOGbaaQ</recordid><startdate>20211123</startdate><enddate>20211123</enddate><creator>Morales-Núñez, José Javier</creator><creator>Muñoz-Valle, José Francisco</creator><creator>Torres-Hernández, Paola Carolina</creator><creator>Hernández-Bello, Jorge</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2272-9260</orcidid><orcidid>https://orcid.org/0000-0001-8004-1811</orcidid></search><sort><creationdate>20211123</creationdate><title>Overview of Neutralizing Antibodies and Their Potential in COVID-19</title><author>Morales-Núñez, José Javier ; Muñoz-Valle, José Francisco ; Torres-Hernández, Paola Carolina ; Hernández-Bello, Jorge</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-1b4999022ee2a94477c808e926bcfd5c080089e624838b77f543bb4c3e8fd01d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Antibody response</topic><topic>Antigens</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Cytotoxicity</topic><topic>Enzymes</topic><topic>Glycoproteins</topic><topic>Herd immunity</topic><topic>Infections</topic><topic>monoclonal antibodies</topic><topic>neutralization assays</topic><topic>Neutralizing</topic><topic>neutralizing antibodies</topic><topic>Pathogens</topic><topic>Peptides</topic><topic>Proteins</topic><topic>Review</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Viral infections</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morales-Núñez, José Javier</creatorcontrib><creatorcontrib>Muñoz-Valle, José Francisco</creatorcontrib><creatorcontrib>Torres-Hernández, Paola Carolina</creatorcontrib><creatorcontrib>Hernández-Bello, Jorge</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Vaccines (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morales-Núñez, José Javier</au><au>Muñoz-Valle, José Francisco</au><au>Torres-Hernández, Paola Carolina</au><au>Hernández-Bello, Jorge</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overview of Neutralizing Antibodies and Their Potential in COVID-19</atitle><jtitle>Vaccines (Basel)</jtitle><addtitle>Vaccines (Basel)</addtitle><date>2021-11-23</date><risdate>2021</risdate><volume>9</volume><issue>12</issue><spage>1376</spage><pages>1376-</pages><issn>2076-393X</issn><eissn>2076-393X</eissn><abstract>The antibody response to respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a major focus of COVID-19 research due to its clinical relevance and importance in vaccine and therapeutic development. Neutralizing antibody (NAb) evaluations are useful for the determination of individual or herd immunity against SARS-CoV-2, vaccine efficacy, and humoral protective response longevity, as well as supporting donor selection criteria for convalescent plasma therapy. In the current manuscript, we review the essential concepts of NAbs, examining their concept, mechanisms of action, production, and the techniques used for their detection; as well as presenting an overview of the clinical use of antibodies in COVID-19.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>34960121</pmid><doi>10.3390/vaccines9121376</doi><orcidid>https://orcid.org/0000-0002-2272-9260</orcidid><orcidid>https://orcid.org/0000-0001-8004-1811</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2076-393X
ispartof Vaccines (Basel), 2021-11, Vol.9 (12), p.1376
issn 2076-393X
2076-393X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_6ab2dec5ee6a4f3d971641e938aee4c5
source Publicly Available Content Database; PubMed Central
subjects Antibodies
Antibody response
Antigens
Coronaviruses
COVID-19
COVID-19 vaccines
Cytotoxicity
Enzymes
Glycoproteins
Herd immunity
Infections
monoclonal antibodies
neutralization assays
Neutralizing
neutralizing antibodies
Pathogens
Peptides
Proteins
Review
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccine efficacy
Vaccines
Viral infections
Viruses
title Overview of Neutralizing Antibodies and Their Potential in COVID-19
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T23%3A48%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overview%20of%20Neutralizing%20Antibodies%20and%20Their%20Potential%20in%20COVID-19&rft.jtitle=Vaccines%20(Basel)&rft.au=Morales-N%C3%BA%C3%B1ez,%20Jos%C3%A9%20Javier&rft.date=2021-11-23&rft.volume=9&rft.issue=12&rft.spage=1376&rft.pages=1376-&rft.issn=2076-393X&rft.eissn=2076-393X&rft_id=info:doi/10.3390/vaccines9121376&rft_dat=%3Cproquest_doaj_%3E2615113414%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c487t-1b4999022ee2a94477c808e926bcfd5c080089e624838b77f543bb4c3e8fd01d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2612845807&rft_id=info:pmid/34960121&rfr_iscdi=true